MarginsXMarginsX
Home › Markets › Health Care › ANAB

AnaptysBio Inc. (ANAB)

ANAB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$45.73
-1.12% on the day
Market cap
$1.4B
Small cap
Revenue · 2025
$234.6M
+157.0% on 2024
Net income · 2025
-$13.2M
-5.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 10-KT (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1370053/000119312526396696/0001193125-26-396696-index.htm. Net income: SEC 10-KT (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerANAB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2017
SEC CIK0001370053
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$234.6M
Net income-$13.2M
Operating income$226.9M
Net margin-5.6%
Operating margin96.7%
Revenue growth+157.0%
Cash$138.2M
Total assets$364.4M
P/E (computed)Net income was not positive
P/S (computed)5.8×

Warning signs

Cash runway
Cash-flow positive
$135.4M cash at September 30, 2026
Share count, 1 year
-28.4%
2025-10-30 to 2026-11-09 · -25.4% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$9.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$135.4M cash; operating cash flow $9.0M a quarter.Report 2026-09-30
Shares outstanding29,729,847 (2026-11-09); 27,688,470 a year earlier; 26,575,178 three years earlier. 1y figure adjusted for split (1.5-for-1 overall); 3y figure adjusted for split (1.5-for-1 overall).Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United StatesPCAOB Form AP 2026-10-15
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $9.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$30.3M$3.9M-$9.5M$135.4MNo debt tags$191.6M10-Q 2026-11-12
Q2 2026
2026-06-30
$27.5M$183.9M-$26.6M$133.8MNo debt tags$237.6M10-KT 2026-09-21
Q1 2026
2026-03-31
$25.6M-$52.9M-$25.9M$248.5MNo debt tags$232.4M10-Q 2026-05-12
Q4 2025
2025-12-31
$108.2M$49.6M$98.0M$138.2MNo debt tags$234.6M10-KT 2026-09-21
Q3 2025
2025-09-30
$76.3M$15.1M-$27.4M$109.8MNo debt tags$169.5M10-Q 2026-11-12
Q2 2025
2025-06-30
$22.3M-$38.6M-$40.2M$44.3MNo debt tags$123.2M10-Q 2025-08-06
Q1 2025
2025-03-31
$27.8M-$39.3M-$10.7M$98.6MNo debt tags$111.9M10-Q 2026-05-12
Q4 2024
2024-12-31
$43.1M-$21.8M-$66.7M$23.1MNo debt tags$91.3M10-KT 2026-09-21

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-11-15
Latest annual report10-KT2026-09-21
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-06-29

Source: SEC EDGAR submissions feed, 728 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.4%
1 month+1.4%
3 months-17.4%
Year to date+43.1%
1 year+108.6%
From 52-week high-33.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B
DMRADamora Therapeutics Inc.$22.50+4.14%$1.4B
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier